Comprehensive identification of mutational cancer driver genes across 12 tumor types by Tamborero, David et al.




Comprehensive identification of mutational 
cancer driver genes across 12 tumor types 
 
 
David Tamborero1,#, Abel Gonzalez-Perez1,#, Christian Perez-Llamas1, Jordi Deu-
Pons1, Cyriac Kandoth2, Jüri Reimand3, Michael S. Lawrence4, Gad Getz4, Gary D. 




1 Research Unit on Biomedical Informatics, Department of Experimental and Health 
Sciences, Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, Spain 
 
2 The Genome Institute, 5 Department of Genetics, 6 Department of Medicine, 7 
Siteman Cancer Center, Washington University in St. Louis, MO 63108, USA 
 
3 The Donnelly Centre, University of Toronto, Toronto, Canada 
 
4 Broad Institute, Massachusetts Institute of Technology and Harvard University, 
Cambridge, MA 02142; 
 
8 Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain 
 
# These authors contributed equally to this work 
 
* To whom correspondence should be addressed. Tel: +34 93 3160507; Fax: +34 93 




Supplementary Figure 1. Results of combining the pan-cancer analysis and the 
per-project analyses.  
 
A) Venn diagram comparing the HCDs retrieved by the pan-cancer analysis with 
those obtained by any of the per-project analyses. Note that the increase in statistical 
power emerging from the combination of the 3205 samples from the 12 tumor types 
in pan-cancer permits the detection of 64 HCDs that don't appear in any per-project 
analysis. They are probably below the threshold of detections of the methods in the 
per-project analyses, because they are mutated at very low frequencies in each 
tumor type, but rather ubiquitously mutated across tumor types. (This is shown in 
panel C.) Pooling all samples together thus allows them to reach the critical point at 
which methods are able to analyze them and nominate them as likely drivers.  
 
B) Details of the 46 HCDs retrieved only by per-project analyses: the histogram at 
the left depicts the number of these genes that were selected by each method, and 
the histogram at the right depicts in which cancer project they were identified. Note 
that they can be selected by more than one method and/or in more than one per-
project analysis. Mutations in these genes are concentrated in one or few tumor 
types so that when they are probed for the signals of positive selection across the 
3205 pan-cancer samples, these mutations are probably diluted with respect to the 
methods' backgrounds. 
 
C) Histogram of the number of samples with PAMs in each cancer type for the 64 
HCDs retrieved uniquely by the pan-cancer analysis approach and the signals of 
positive selection they showed. Interestingly, very few of these genes are included in 
the cancer genes census, probably because their low recurrence had allowed them 




Supplementary Figure 2. General flowchart of the approach taken to identify 
putative mutational cancer drivers from the combination of four complementary 
approaches. 	  	  
For further details, see the Methods section. 
 
 Briefly, mutations detected in genes across the 3205 samples of the 12 tumor types 
in pan-cancer were analyzed with four complementary methods (MuSiC, 
OncodriveFM, OncodriveCLUST, and ActiveDriver). The aim was to detected genes 
with signals of being positively selected upon mutations in these tumor samples. 
Each method gave as output a prioritized list of driver candidates cut at different 
lengths as explained in Supplementary Figure 1A. The genes in the 48 lists 
generated after running the five methods on the pan-cancer dataset and on each 
tumor type's dataset separately –after careful expression filtering– were integrated 
into three short lists. Theses were: the genes with various signals of positive 
selection (VSGs), the known cancer genes with one signal of positive selection 
(KCGs), and the genes with one signal of positive selection not in the cancer gene 
census (OSGs). The former two categories integrated the High-confidence drivers 
(HCD) list. Genes in the latter category were probed for functional interactions with 
HCDs and those with such functional connections were rescued and added to the 
HCD list. On the other hand, OSGs involved in protein-protein interactions with HCDs 
were placed in a separate group of Candidate Drivers, or CDs. Finally, 40 genes 
detected by MutSig as significantly mutated which were not previously in the HCD list 
were included within it for completion.	  
	  	  
Supplementary Figure 3. Venn diagram showing the overlap between the genes 
selected by MutSig and those selected by the initial combination of the four other 
methods.  
 
The numbers represent the results of the pan-cancer analysis and each per-project 
analyses. The VSG list contains genes exhibiting various signals of positive 
selection; The KGC list contains known cancer genes (i.e. those included in the 
Cancer Gene Census) that showed one signal of positive selection; and the OSG list 
includes the remaining genes in which only one signal of positive selection was 
identified and are not in the CGC. Six genes that had been nominated as CDs by our 
approach (see Supplementary Figure 3) were identified by MutSig as significantly 
mutated and thus added to the HCD list. Thirty-four others detected by MutSig and 
not in OSG list were also added to the HCD list. Therefore, in summary, forty genes 
highlighted as likely drivers by MutSig were incorporated to our catalog of HCDs, as 
explained in the main paper and in the Methods section. 
	  	  
	  
Supplementary Figure 4. 51 HCDs bearing PAMs in more than 10% of samples of 
at least one cancer type. The number in the heat-map indicates the number of 
samples with PAMs in the gene and the color indicates the frequency. The 51 genes 
are ordered according to the overall frequency in the whole dataset. The annotations 
at the right side indicate if the gene is in the Cancer Gene Census (CGC), if it is 
detected by MuSiC, OncodriveFM, OncodriveCLUST and/or MuSiC, and if the gene 
is identified as significantly mutated by MutSig. ‘Novel’ drivers discussed at length in 
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Supplementary Figure 5. Top 75 HCDs showing clearer preference for acting as 
mutational drivers in certain tumor types according to odds ratio calculation. The 
numbers in the heatmap indicate the number of samples with PAMs in the gene and 
the color indicates the Fisher’s odds ratio. The 75 genes are ordered according to the 
overall frequency in the whole dataset. The annotations at the right side indicate if 
the gene is in the Cancer Gene Census (CGC), if it is detected by MuSiC, 
OncodriveFM, OncodriveCLUST and/or MuSiC, and if the gene is identified as 
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Supplemental Figure 6. A) Venn diagram showing HCDs that were also selected as 
recurrently altered according to Gistic and/or biased towards larger misregulation 
according to the OncodriveCIS analysis of the pan-cancer data set. For the latter, we 
have taken the 100 top-ranking genes due to amplifications and deletions; these lists 
exhibited a significant enrichment of HCDs (Fisher's p<1e-04). B) List of genes 
selected by Gistic within a region either significantly amplified (red squares) or 
deleted (blue squares). C) Expression boxplots of the HCDs selected by 
OncodriveCIS depending on their CNAs. Top color bars depict the proportion of 




Supplemental Figure 7. Upper panel: Boxplot of the protein affecting mutations per 
cancer project. Numbers above the plot depict the total number of mutations in each 
of these projects, whereas numbers below the plot -between parenthesis- depict the 
number of samples. 
Lower panel: Number of drivers that are predominantly mutated in each tumor type, 
as identified by following the criteria defined in the Methods section.  
 
 
Supplementary Table 1. Details of the datasets used for the analysis, including the 
number of samples of each cancer site, the number of PAMs, the number of PAMs in 
HCDs and the number of samples with PAMs in at least one HCD. 
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in at least 
one HCD 
BLCA Bladder Urothelial Carcinoma 98 160 (157) 9.5 (7.5) 98 (1.0) 
BRCA Breast invasive carcinoma 762 28 (27) 3 (2) 710 (0.93) 
COADREAD Colon and Rectum adenocarcinoma 193 65 (47) 5 (2) 193 (1.0) 
GBM Glioblastoma multiforme 290 51 (23) 4 (3) 272 (0.94) 
HNSC Head and Neck squamous cell carcinoma 301 97 (79) 6 (5) 299 (0.99) 
KIRC  Kidney renal clear cell carcinoma 417 45 (24) 3 (3) 393 (0.94) 
LAML Acute Myeloid Leukemia 193 8 (7) 2 (3) 165 (0.85) 
LUAD Lung adenocarcinoma 226 183 (248) 9 (8) 221 (0.98) 
LUSC Lung squamous cell carcinoma 174 209 (123) 9 (7) 172 (0.99) 
OV Ovarian serous cystadenocarcinoma 316 40 (276) 2 (2) 312 (0.99) 
UCEC Uterine Corpus Endometrioid Carcinoma 230 48 (153) 6 (9) 228 (0.99) 
 
 
Supplementary Table 2. List of HCDs and CDs with their signals of positive 




Supplementary Table 3. Highly enriched (FDR < 0.001) biological processes for 
HCDs.  
 
After constructing the Functional Interaction network as explained in Methods, it was 
partitioned into clusters employing the Reactome FI plugin and the resulting clusters 
were probed for enrichment of Biological Processes Gene Ontologies terms. The 
table presents selected highly enriched  Biological Processes Gene Ontologies terms 







GOBP term Gene fraction Genes in 
GOBP













nuclear mRNA splicing, via 
spliceosome
0.0119 105 8 0 <1.000e-03 SF3B1,PRPF8,PCBP1,U2AF1,CCAR1,DHX9,R
BMX,SMC1ARNA splicing 0.0208 184 8 0 <2.500e-04 NONO,SF3B1,PRPF8,U2AF1,PABPC1,PPP2R
1A,DDX5,RBMXmRNA transport 0.0058 51 5 0 <2.000e-04 NUP98,NUP93,NUP214,RANBP2,TPR
chromatin modification 0.0136 120 15 0 <1.000e-03 ARID1A,SUZ12,BCOR,MLL,NCOR1,EZH2,TB
L1XR1,RB1,CARM1,NSD1,ARID2,CHD8,CHD
4,CHD3,SETD2
histone methylation 0.0006 5 3 0 5.63E-04 SUZ12,CARM1,NSD1
G1/S transition of mitotic 
cell cycle
0.0041 36 8 0 <1.667e-04 CDKN2A,CDKN2C,CUL1,CDKN1A,CDKN1B,
ACVR1B,RB1,CCND1cell cycle arrest 0.0087 77 10 0 <1.429e-04 CDKN2A,CDKN2C,CUL1,STK11,CDKN1A,CD
KN1B,TP53,RB1,TCF7L2,APCnegative regulation of cell 
cycle
0.0111 98 8 0 6.15E-04 WT1,TSC2,TP53,RB1,VHL,NF1
response to DNA damage 
stimulus
0.0208 184 11 0 <1.000e-03 BLM,TP53BP1,BRCA2,CHEK2,ATR,WRN,AT
M,BRCA1,MDC1,FANCA,BARD1DNA repair 0.0135 119 6 0 <5.000e-04 BLM,TP53BP1,ATR,ATM,MDC1,FANCA
double-strand break repair 
via homologous 
recombination
0.0017 15 3 0 <3.333e-04 BLM,BRCA2,BRCA1
replication fork protection 0.0002 2 2 0 5.00E-04 BLM,BRCA2
replication fork processing 0.0002 2 2 0 5.00E-04 BLM,WRN
androgen receptor 
signaling pathway
0.0038 34 8 0 <2.000e-04 CTNNB1,MED12,ARID1A,MED13,MED17,AR,
RB1,NCOA3negative regulation of cell 
growth
0.0058 51 8 0 <1.111e-04 CDKN2A,CDKN2C,SMAD4,CDKN1A,CDKN1B
,ACVR1B,TP53,RB1negative regulation of cell 
proliferation
0.0214 189 12 0 <9.091e-05 CDKN2A,CDKN2C,CUL1,STK11,AXIN2,SMAD
4,CDKN1A,CDKN1B,TSC2,RB1,CEBPA,VHLprotein amino acid 
phosphorylation





0.0014 12 4 0 1.00E-03 PIK3CA,PIK3CG,PIK3CB,PIK3R1
peptidyl-tyrosine 
phosphorylation
0.0019 17 4 0 4.00E-04 FES,PDGFRA,KIT,ABL1
positive regulation of cell 
proliferation
0.0188 166 8 0 5.71E-04 HRAS,MATK,LYN,LIFR,KIT,KRAS,FLT3,NRAS
phosphoinositide-mediated 
signaling
0.0032 28 4 0 8.18E-04 PIK3CA,PIK3CG,PIK3CB,ERBB2
transmembrane receptor 
protein tyrosine kinase 
signaling pathway
0.0078 69 5 0 9.29E-04 NCOA4,ADORA2A,ERBB2,KIT,FLT3
positive regulation of MAP 
kinase activity
0.0014 12 3 0 9.33E-04 EGFR,ERBB2,KIT
positive regulation of cell 
migration
30 4 0.0034 0 2.50E-04 EGFR,IRS2,PDGFRA,PIK3R1
Wnt receptor signaling 
pathway through beta-
10 3 0.0011 0.0002 4.43E-03 CTNNB1,TCF7L2,APC
Supplementary Table 3
Supplementary Table 4. Information from literature about the function and previous 
evidence of cancer involvement of a set of novel mutational drivers identified in this 
study. Genes discussed in the Table are shown as examples in the manuscript and 










Evidences of involvement in
cancer
Comments








polarity (S. E. Williams et




Frequently mutated in head and
neck squamous cell carcinomas











is significantly associated with
poor survival in laryngeal
carcinoma (Dumitru et al. 2013)
Ahnak protein was shown to
function as the signalling
scaffold interacting with the
multiple protein complex of Erk,
PAK, and p21-activated kinase-
interacting exchange factor β.
Ahnak protein plays an
important scaffolding function
connecting Erk and Rac
activation in PDGF-dependent









NAV3 copy number changes are
frequent in CRC and in
adenomas, and upregulation of
IL23R, following NAV3 silencing,
strongly correlates with Dukes'
staging and lymph node
metastases. This suggests that
NAV3 has a role in linking tissue
inflammation to cancer
development in the colon
(Carlsson et al. 2012).
FBN2 Fibrillin 2 The protein encoded by
this gene is a component
of connective tissue
microfibrils and may be
involved in elastic fiber







It is a tumor suppressor gene
silenced by aberrant DNA
methylation in renal cell
carcinoma. It may contribute to
the dysregulation of the complex
network of signalling pathways
regulated by TGF-b (Kikuyama










Probable role in mitotic
spindle regulation and
coordination of mitotic
processes. May have a
preferential role in
regulating neurogenesis.




activities in human melanoma
cells (Kabbarah et al. 2010)
ASPM inhibition by siRNA-
mediated knockdown was found
to inhibit tumor cell proliferation
and neural stem cell proliferation
in glioma cells, further
supporting its role as a potential





It inhibits the enhancer
element of the AFP gene
by binding to its AT-rich
core sequence. Regulator
of myoblasts differentiation
through the binding to the




promoter in gastric cancer
ATBF1 encodes a transcription
factor that negatively regulates
AFP and MYB but transactivates
CDKN1A. 
Frequent somatic mutations of
this gene were reported in



















of nicotinic acid adenine
dinucleotide phosphate
(NAADP) receptors,
increase in lysosomal pH,
and calcium release from
lysosomes.
Dominant mutations in
the LRRK2 gene are the most




NLRP3 May function as an
inducer of apoptosis.
Interacts selectively with
ASC and this complex
may function as an







activity of RELA. Activates
caspase-1 in response to
a number of triggers
including bacterial or viral
infection which leads to











Promotes the exchange of
GDP by GTP. Together
with leukocyte antigen-
related (LAR) protein, it




for cell migration and cell
growth.
Rho-GEFs Guanine nucleotide
exchange factors (GEFs) that
promotes GTP loading onto the
guanosine triphosphatases
(GTPases) Rho and Rac,




The ZNF91 gene encodes
a zinc finger protein of the
KRAB (Kruppel-associated
box) subfamily (Bellefroid




Potent mitogen for mature
parenchymal hepatocyte
cells, seems to be a
hepatotrophic factor, and
acts as growth factor for a
broad spectrum of tissues
and cell types. Activating
ligand for the receptor
tyrosine kinase MET by
binding to it and promoting
its dimerization.









residues of the C-terminal




migratory ability of cell lines. In a
xenograft model, histological
analysis revealed that the
expression of Snail, a cell-
adhesion-suppressing
transcription factor, was
dramatically increased in ALVA-
ActRIBCA tumors, indicating
epithelial mesenchymal
transition (EMT). Finally, mice
bearing ALVA-ActRIBCA cells
developed multiple lymph node






Intermediate of the role of







substrates and blocks cell
cycle (Insinga et al. 2013).
Plays a partial role in induced
pluripotent stem cells formation
probably by slowing cell division.
Polymorphisms in this gene
have been associated to
increased risk of several cancers
(F. Liu et al. 2013; Zhongqiu
Wang et al. 2012; Ying et al.
2011). It's also been identified as
transcriptionally missregulated in










Binds to and prevents the
activation of cyclin E-
CDK2 or cyclin D-CDK4
complexes, and thus
controls the cell cycle
progression at G1 (J. Lee
& Sung Soo Kim 2009).
Its downregulation is often
correlated with poor prognosis in
several types of human cancers.
The protein can also be
functionally inactivated by
cytoplasmic localization or by
phosphorylation, but it's seen
only rarely mutated(Carracedo
et al. 2008; C. Yao et al. 2008;











Cell cycle checkpoint gene
required for cell cycle
arrest and DNA damage
repair in    response to
DNA damage. This kinase
has been shown to
phosphorylate checkpoint
kinase CHK1, checkpoint
proteins RAD17,     and
RAD9, as well as tumor
suppressor protein BRCA1
(Dart et al. 2004).
Polymorphisms in this gene
have been associated to
increased cancer susceptibility
(Heikkinen et al. 2005;
Zienolddiny et al. 2006) and
somatic mutations have been
linked to DNA repair defective
cancers with hypermutator

















and regulation of gene
expression in differentiated
tissues. Is thought to act
as a 'pioneer' factor,
opening the compacted
chromatin for other
proteins (Bernardo & Keri
2012).
Its aberrant expression in
several tissue types
transcriptionally alters several
known cancer drivers, thus
promoting tumorigenesis
(Williamson et al. 2006;














Its expression is known to be
missregulated in several
malignancies (Mirosevich et al.
Cell
signaling/proliferation
module in Figure 2A.
establishment of tissue-
specific gene expression
and regulation of gene
expression in differentiated
tissues. Is thought to act
as a 'pioneer' factor
opening the compacted
chromatin for other
proteins (Rausa et al.
2003).
2006; M. Liu et al. 2012). It's
been linked to promotion of
metastases in some tumor types









required for the cohesion
of sister chromatids after
DNA replication (Sumara
et al. 2000).
Upon somatic mutations or
deletions, STAG2 is known to be
involved both in leukemias and
solid cancers through the
development of aneuploidy
(Chung et al. 2012; M S Kim et












Encodes an isoform of the
catalytic subunit of
phosphoinositide 3-kinase
(PI3K). These kinases are
important in signaling
pathways involving
receptors on the outer
membrane of eukaryotic
cells and are named for
their catalytic subunit. The




processes, such as cell
growth and cell cycle entry
(Kumar et al. 2011;
Marqués et al. 2008).
While it's been shown to harbor
somatic mutations implicated in
tumorigenesis in some cancer
types. PIK3CB de-regulation is
very important in PTEN-deficient
tumors, where it directly affects














Encodes a protein that
belongs to the PI3/PI4-
kinase family of proteins.




3-hydroxyl group of the
inositol ring. It is an
important modulator of
extracellular signals,
including those elicited by
E-cadherin-mediated cell-
cell adhesion, which plays




(Vogelmann et al. 2005).
Both, genetic and epigenetic
alterations of PIK3CB have been
linked to the progression of
several cancer types.
Specifically, it has been related
with cancer invasion,
metastasis, and poor cell
differentiation (Sasaki et al.
2000; Semba et al. 2002).
Cell
signaling/proliferation
module in Figure 2A.
PI3K pathway in
Figure 3A.




coactivator involved in the
regulated transcription of
nearly all RNA polymerase
II-dependent genes.




to the basal RNA
polymerase II transcription
machinery (Y. K. Kang et
al. 2002; Gustafsson &
Samuelsson 2001; Davis
et al. 2013).
degradation by the known tumor
suppressor FBXW7. Alterations
in both FBXW7 and MED13 –for
example through  amplification
in several cancers (Paz et al.
2007)– are thus hypothesized to
be related to oncogenesis and
tumor progression (Davis et al.
2013).
signaling/proliferation








Mediator complex, a co-
activator involved in the
regulated transcription of
nearly all RNA polymerase
II-dependent genes.




to the basal RNA
polymerase II transcription
machinery (Xiaohui Liu et
al. 2008)
It has been shown in prostate




proliferation, inhibits cell cycle
progression, and increases
apoptosis. Therefore, it appears
to play a role in tumorigenesis at
least in this tissue through
transcriptional de-regulation
(Vijayvargia et al. 2007)
Cell
signaling/proliferation
















CREB binding protein as
part of a multisubunit co-
activation complex.
Both tumorigenesis predisposing
polymorphisms (Burwinkel et al.
2005) and somatic alterations –
mostly  in transcriptional level
due to copy number changes
(Henke et al. 2004)– have been










PKC (Protein kinase C)
family members –family of
serine- and threonine-
specific protein kinases
activated by calcium and
diacylglycerol–
phosphorylate a wide
variety of protein targets
and are known to be
involved in diverse cellular
signaling pathways
(Durgan et al. 2007; Ren
et al. 2002).
Its cellular location has been
shown to play an important role
in balancing between its
proapoptotic and antiapoptotic
functions and in the activation of
downstream signaling pathways
(Gomel et al. 2007). It is
frequently lost –and coherently
down-regulated– in squamous











RHEB Ras Homolog Vital in regulation of Through its involvement in the Cell
Enriched In
Brain
growth and cell cycle
progression due to its role
in the insulin/TOR/S6K
signaling pathway (Long et
al. 2005; Tee et al. 2005).
TOR pathway, and via
transcriptional de-regulation, it is
known to participate in
oncogenesis (Kobayashi et al.
2010).
signaling/proliferation
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